Fiorenzo Santoleri, Felice Musicco, Chiara Fulgenzio, Paolo Abrate, Laura Pestrin, Enrico Pasut, Germana Modesti, Romina Giannini, Stefania De Rosa, Mariantonietta Piccoli, Grazia Mingolla, Eva Zuzolo, Pietro Gazzola, Martina Roperti, Gabriella Pieri, Valentina Montresor, Isabella Martignoni, Marco Gambera, Roberto Langella, Gabriella Tinari, Concetta Spoltore, Cristina Roberti, Letizia Di Fabio, Laura Grossi, Francesca Guarino, Francesco De Vita, Ruggero Lasala, Alberto Costantini
Aim: This study aims to investigate drug utilization patterns in the treatment of psoriasis (PsO) from 1 to 5 years in a real-life setting with Adalimumab (Ada), Etanercept (Eta), Ustekinumab (Ust), Golimumab (Gol), Ixekizumab (Ixe), Secukinumab (Sec) and Apremilast (Apr). Materials & methods: Data from an observational study were used to calculate adherence using the Proportion of Days Covered (PDC) method and persistence. Results & conclusion: Treatment adherence was found to be good for all the drugs studied across all years of analysis, while persistence was suboptimal, showing a marked decrease from the third year of study onward...
April 23, 2024: Immunotherapy